Japan’s Teijin Pharma and Tokyo-based Aska Pharmaceutical have entered a joint research agreement to accelerate the discovery of novel small-molecule drug candidates targeting gynecological diseases. The collaboration pairs Teijin Pharma’s AI-driven drug discovery and computer-aided molecular design capabilities with Aska’s deep expertise in obstetrics and gynecology.
The partnership is focused on early-stage drug discovery – identifying and optimizing compounds that interact with specific molecular targets relevant to gynecological conditions. Teijin Pharma has built a research platform using simulations and predictive models designed to shorten drug discovery timelines and improve success rates, while Aska brings pharmacological evaluation expertise grounded in clinical needs across women’s health.
No specific disease targets or financial terms were disclosed. Aska Pharmaceutical is a specialty pharma company with a portfolio spanning obstetrics, gynecology, urology, and internal medicine. Teijin is a technology-driven global group (TSE: 3401) with consolidated revenue of JPY 1,005.5 billion (~$6.7B), operating across high-performance materials and healthcare solutions.
